G6PD and breast cancer: In summary, our study identifies for the first time the tremendous therapeutic potential of pyrotinib combined with chrysin in treating HER2-positive breast cancer but also sheds light on the functional role of miR-16-5p/ZBTB16/G6PD axis in the anti-HER2 therapeutic process.